|
Home Page
About SAEN
Articles and Reports
Contact Us
Events and Campaigns
Fact Sheets
Financial Information
How You Can Help
Make a Donation, Please!
Media Coverage
Newsletters
Petitions
Picture Archive
Press Releases
Resources and Links
Grass Roots Org. List

 |
Stop Animal
Exploitation NOW!
S. A. E. N.
"Exposing the truth to wipe
out animal experimentation"

Government Grants Promoting Cruelty to Animals
McLean Hospital, Belmont, MA
JACK H. MENDELSON - Primate Testing - 2006
Grant Number: 5P01DA014528-050004
Project Title: BIOLOGIC APPROACHES TO COCAINE ABUSE TREATMENT
PI Information: PROFESSOR JACK H. MENDELSON,
jmendel@mclean.harvard.edu
Abstract: Project V:
Biologic Approaches to Cocaine Abuse Treatment is part of a new
application for a NIDA Program Project (P-01) entitled Cocaine and
Polydrug Abuse: New Medication Strategies. Two series of studies are
proposed to test the hypothesis that endocrine and neuroendocrine
systems may be useful targets for the development of novel medication
strategies for cocaine abuse. The first series of studies is based on
our discovery that administration of synthetic luteinizing hormone
releasing hormone (LHRH) not only increased plasma levels of luteinizing
hormone (LH), but also dose-dependently decreased peak plasma levels of
free (unbound) cocaine in both rhesus monkeys and humans following i.v.
cocaine injection. he LH glycoprotein molecule shares structural
features with other cocaine binding substrates including the dopamine
transporter, and plasma levels of circulating glycoproteins (e.g.,
alpha- acid glycoprotein) are known to bind to cocaine and influence
levels of free cocaine in plasma. In pharmacokinetic studies in rats, we
will assess the ability of synthetic LHRH injections to alter plasma and
brain levels of cocaine after i.v. administration. In complementary
behavioral studies, we will evaluate the effects of synthetic LHRH on
both cocaine discrimination and cocaine self-administration in rhesus
monkeys. If our hypothesis is correct, increased LHRH levels will reduce
brain levels of cocaine in rats and cocaine's abuse-related effects in
monkeys. Such findings would encourage further studies to identify the
relevant subunit of the LH glycoprotein that binds to cocaine, and may
provide a new approach to the development of anti-cocaine medications. A
second series of studies is based on our recent findings that acute
administration of cocaine stimulates an immediate release of
adrenocorticotropin hormone (ACTH) from the anterior pituitary and a
subsequent release of cortisol from the adrenal gland in rhesus monkeys
and in humans (Projects III and IV). Clinical reports of a significant
temporal concordance between increased plasma cocaine levels, cocaine-
induced increases in ACTH and subjective reports of cocaine-induced
"high" further suggest that the hypothalamic-pituitary adrenal (HPA)
axis may contribute to cocaine's abuse-related effects. Using newly
available systematically-active CRF antagonists, we will test the
hypothesis that activation of HPA systems contributes to cocaine's
discriminative stimulus and reinforcing effects in rats and monkeys.
Additional studies in rats will compare peptidic and non-peptidic CRF
antagonists after central and systemic administration to assess
pharmacokinetics and to identify brain and/or pituitary regions involved
in the putative anti-cocaine effects of CRF antagonists. In these basic
neurobiological and pharmacological studies, experimental designs (e.g.,
doses and time course of cocaine, LHRH and CRF antagonists) will be
based, in par, on findings from Projects II-IV. Collectively, these
studies will complement findings from other inter- related projects on
cocaine's influence on endocrine function and will address the question
of whether endocrine and/or neuroendocrine systems may be manipulated to
attenuate cocaine's abuse-related effects and/or strengthen anti-cocaine
effects of other candidate treatment medications.
Thesaurus Terms:
cocaine, drug abuse, drug abuse chemotherapy, drug addiction antagonist,
nonhuman therapy evaluation
corticotropin releasing factor, gonadotropin releasing factor,
hypothalamic pituitary adrenal axis, luteinizing hormone,
neuropharmacology, neurotransmitter antagonist, pharmacokinetics, self
medication, substance abuse related behavior
Macaca mulatta, behavioral /social science research tag,
catheterization, intravenous administration, laboratory rat
Institution: MC LEAN HOSPITAL (BELMONT, MA)
115 MILL ST
BELMONT, MA 02478
Fiscal Year: 2006
Department:
Project Start:
Project End:
ICD: NATIONAL INSTITUTE ON DRUG ABUSE
IRG: NIDA
Vol. 281, Issue 1, 70-83, 1997
The Effects of Chronic Cocaine Self-Administration on
the Menstrual Cycle in Rhesus Monkeys
Nancy K. Mello, Jack H. Mendelson, Maureen Kelly, Nicolas Diaz-Migoyo
and J. Wallis Sholar
Alcohol and Drug Abuse Research Center, McLean Hospital-Harvard Medical
School, 115 Mill Street, Belmont, MA 02178
Operant Behavioral Procedures and Apparatus
Monkeys lived in a well-ventilated stainless steel chamber equipped with
an operant panel, a banana pellet feeder and a water dispenser. Drug
injections were delivered by a syringe pump in a single pulse that
dispensed 0.1 ml of fluid over 0.9 sec. The operation of the syringe
pump (Model 981210, Harvard Apparatus, Inc., South Natick, MA) was
audible to the monkey. Schedules of reinforcement were programmed by
custom-designed software and run on Apple II GS computers.
Monkeys worked at an operant task for food and for i.v. cocaine
injections on a second-order schedule of reinforcement (FR2 [VR:16S])
that required an average of 32 responses for each food pellet or cocaine
injection. Food availability and cocaine availability conditions were
associated with different colored stimulus lights (S+) projected on a
translucent Plexiglas response key (2-in. diameter) in the center of the
operant panel. The key was dark during time-out periods when responses
had no programmed consequences. When a food pellet or drug injection was
delivered, the appropriate colored stimulus light (S+) (red or green)
was illuminated for 1 sec on one of the three circles (3/4-in. diameter)
located in a vertical column below the response key. Flashes of the
1-sec colored stimulus lights (S+) also signaled the completion of each
successive VR component of a second-order schedule response requirement.
When cocaine was not available because of catheter loss, the response
key was dark except during food sessions.
Each experimental day consisted of four food availability and four drug
availability sessions. Food sessions began at 11 A.M., 3 P.M., 7 P.M.
and 7 A.M. each day, and drug sessions began 1 hr later at 12 noon, 4
P.M., 8 P.M. and 8 A.M. Consecutive food and drug sessions were
separated by time-out periods 2 hr (1-3 P.M., 5-7 P.M. and 9-11 A.M.) or
10 hr in duration (9 P.M.-7 A.M.). The response key was dark during
time-out periods, and responses had no programmed consequences. Each
food or drug session lasted 1 hr or until 100 banana pellets (1 gm) or
20 cocaine injections (0.10 mg/kg/injection) were delivered. Cocaine
injections were limited to 80 per day (8 mg/kg/day) to minimize the
possibility of adverse drug effects.
Surgical Procedures
After operant performance for food was stable on the final schedule of
reinforcement and there was evidence of normal ovulatory base-line
menstrual cycles, each monkey was surgically implanted with an i.v.
double lumen silicon catheter (I.D. 0.028 in., O.D. 0.080 in.) under
aseptic conditions. Monkeys were sedated with ketamine (5 mg/kg s.c.),
and anesthesia was induced with sodium thiopental (10 mg/kg i.v.).
Atropine (0.05 mg/kg) was given to reduce salivation. After insertion of
an intratracheal tube, a surgical level of anesthesia was maintained
with halothane (1-1.5% in oxygen). Catheters were implanted in the
jugular or femoral vein and exited in the mid-scapular region. After
surgery, monkeys were given 200,000 units of Combiotic
Dihydrostreptomycin and Penicillin G i.m. on alternate days for a total
of 5 injections. The i.v. catheter was protected by a tether system
consisting of a custom-fitted nylon vest connected to a flexible
stainless steel cable and fluid swivel (Spaulding Medical Products,
Birmingham, AL), which permitted monkeys to move freely. Catheter
patency was maintained by i.v. cocaine administration and a saline
flush. Fluid swivel and catheter patency were checked manually each day.
A short-acting barbiturate, methohexital sodium (3 mg/kg i.v.), was used
to evaluate catheter patency, if necessary. The catheter was considered
to be patent if i.v. administration of methohexital produced a loss of
righting within 10 sec of its administration. |
Please email: JACK H. MENDELSON,
jmendel@mclean.harvard.edu to protest the inhumane use of animals in this
experiment. We would also love to know about your efforts with this
cause:
saen@saenonline.org
Return to Grants
Return to McLean Hospital, Belmont, MA
Return to Facility Reports and Information
Return to Resources and Links
Rats, mice, birds, amphibians and other animals have
been excluded from coverage by the Animal Welfare Act. Therefore research
facility reports do not include these animals. As a result of this
situation, a blank report, or one with few animals listed, does not mean
that a facility has not performed experiments on non-reportable animals. A
blank form does mean that the facility in question has not used covered
animals (primates, dogs, cats, rabbits, guinea pigs, hamsters, pigs,
sheep, goats, etc.). Rats and mice alone are believed to comprise over 90%
of the animals used in experimentation. Therefore the majority of animals
used at research facilities are not even counted.
|